Last reviewed · How we verify
NCT06590480: RPL-EAP-001
An Expanded Access Program for VO (RP1) in Combination With Nivolumab in Patients With Advanced Melanoma
trial testing RP1 in Advanced Melanoma. No longer available.
Quick facts
| Lead sponsor | Replimune, Inc. |
|---|---|
| Status | NO LONGER AVAILABLE |
| Study type | EXPANDED_ACCESS |
Drugs / interventions tested
Conditions studied
- Advanced Melanoma — all drugs for Advanced Melanoma →
Sponsor
Replimune, Inc.
Who can join
18 and older, any sex, with Advanced Melanoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this EAP is to provide expanded access (i.e., before marketing authorization) to vusolimogene oderparepvec (VO; herein referred to as VO) plus standard-of-care (SOC), nivolumab, for eligible patients diagnosed with advanced melanoma, who, in their treating physician's opinion, could benefit from this treatment.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Oncolytic HSV and cancer drug interactions: Current clinical status and future directions.
Vázquez-Arreguín K, Rivera-Caraballo KA, Ventarapragada D, Chiocca EA, et al · · 2025 · cited 6× · PMID 40702727 · DOI 10.1016/j.ymthe.2025.07.034
Verify or expand the search:
- PubMed search for NCT06590480
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Advanced Melanoma
Currently open trials in the same condition.
- NCT07310784 — A Phase II Trial of LM103 in Advanced Melanoma · Phase 2 · recruiting
- NCT07099430 — A Trial of LBL-024 Monotherapy, LBL-024 Combined With LBL-007 or Toripalimab in Patients With Advanced Melanoma · Phase 1, PHASE2 · recruiting
- NCT05629546 — Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on C · Phase 1 · recruiting
- NCT06264180 — VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3] · Phase 3 · recruiting
- NCT06298734 — High-Intensity Exercise and High-Fiber Diet for Immunotherapy Outcomes in Melanoma Patients: The DUO Trial · NA · recruiting
Other Replimune, Inc. trials
Trials by the same sponsor.
- NCT05733598 — Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC · Phase 2 · recruiting
- NCT06264180 — VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3] · Phase 3 · recruiting
- NCT05743270 — Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN · Phase 2 · withdrawn
- NCT05733611 — RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC · Phase 2 · terminated
- NCT04735978 — Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours · Phase 1 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06590480 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Replimune, Inc.
- Last refreshed: 18 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06590480.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing